Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer : Early Results from the COMPASS Trial
©2017 American Association for Cancer Research..
Purpose: To perform real-time whole genome sequencing (WGS) and RNA sequencing (RNASeq) of advanced pancreatic ductal adenocarcinoma (PDAC) to identify predictive mutational and transcriptional features for better treatment selection.Experimental Design: Patients with advanced PDAC were prospectively recruited prior to first-line combination chemotherapy. Fresh tumor tissue was acquired by image-guided percutaneous core biopsy for WGS and RNASeq. Laser capture microdissection was performed for all cases. Primary endpoint was feasibility to report WGS results prior to first disease assessment CT scan at 8 weeks. The main secondary endpoint was discovery of patient subsets with predictive mutational and transcriptional signatures.Results: Sixty-three patients underwent a tumor biopsy between December 2015 and June 2017. WGS and RNASeq were successful in 62 (98%) and 60 (95%), respectively. Genomic results were reported at a median of 35 days (range, 19-52 days) from biopsy, meeting the primary feasibility endpoint. Objective responses to first-line chemotherapy were significantly better in patients with the classical PDAC RNA subtype compared with those with the basal-like subtype (P = 0.004). The best progression-free survival was observed in those with classical subtype treated with m-FOLFIRINOX. GATA6 expression in tumor measured by RNA in situ hybridization was found to be a robust surrogate biomarker for differentiating classical and basal-like PDAC subtypes. Potentially actionable genetic alterations were found in 30% of patients.Conclusions: Prospective genomic profiling of advanced PDAC is feasible, and our early data indicate that chemotherapy response differs among patients with different genomic/transcriptomic subtypes. Clin Cancer Res; 24(6); 1344-54. ©2017 AACR.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Clinical cancer research : an official journal of the American Association for Cancer Research - 24(2018), 6 vom: 15. März, Seite 1344-1354 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aung, Kyaw L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers, Tumor |
|---|
| Anmerkungen: |
Date Completed 30.09.2019 Date Revised 07.12.2022 published: Print-Electronic ClinicalTrials.gov: NCT02750657 Citation Status MEDLINE |
|---|
| doi: |
10.1158/1078-0432.CCR-17-2994 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM279516134 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM279516134 | ||
| 003 | DE-627 | ||
| 005 | 20231225023138.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-17-2994 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0931.xml |
| 035 | |a (DE-627)NLM279516134 | ||
| 035 | |a (NLM)29288237 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aung, Kyaw L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer |b Early Results from the COMPASS Trial |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.09.2019 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02750657 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2017 American Association for Cancer Research. | ||
| 520 | |a Purpose: To perform real-time whole genome sequencing (WGS) and RNA sequencing (RNASeq) of advanced pancreatic ductal adenocarcinoma (PDAC) to identify predictive mutational and transcriptional features for better treatment selection.Experimental Design: Patients with advanced PDAC were prospectively recruited prior to first-line combination chemotherapy. Fresh tumor tissue was acquired by image-guided percutaneous core biopsy for WGS and RNASeq. Laser capture microdissection was performed for all cases. Primary endpoint was feasibility to report WGS results prior to first disease assessment CT scan at 8 weeks. The main secondary endpoint was discovery of patient subsets with predictive mutational and transcriptional signatures.Results: Sixty-three patients underwent a tumor biopsy between December 2015 and June 2017. WGS and RNASeq were successful in 62 (98%) and 60 (95%), respectively. Genomic results were reported at a median of 35 days (range, 19-52 days) from biopsy, meeting the primary feasibility endpoint. Objective responses to first-line chemotherapy were significantly better in patients with the classical PDAC RNA subtype compared with those with the basal-like subtype (P = 0.004). The best progression-free survival was observed in those with classical subtype treated with m-FOLFIRINOX. GATA6 expression in tumor measured by RNA in situ hybridization was found to be a robust surrogate biomarker for differentiating classical and basal-like PDAC subtypes. Potentially actionable genetic alterations were found in 30% of patients.Conclusions: Prospective genomic profiling of advanced PDAC is feasible, and our early data indicate that chemotherapy response differs among patients with different genomic/transcriptomic subtypes. Clin Cancer Res; 24(6); 1344-54. ©2017 AACR | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a GATA6 Transcription Factor |2 NLM | |
| 650 | 7 | |a GATA6 protein, human |2 NLM | |
| 700 | 1 | |a Fischer, Sandra E |e verfasserin |4 aut | |
| 700 | 1 | |a Denroche, Robert E |e verfasserin |4 aut | |
| 700 | 1 | |a Jang, Gun-Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Dodd, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Creighton, Sean |e verfasserin |4 aut | |
| 700 | 1 | |a Southwood, Bernadette |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Sheng-Ben |e verfasserin |4 aut | |
| 700 | 1 | |a Chadwick, Dianne |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a O'Kane, Grainne M |e verfasserin |4 aut | |
| 700 | 1 | |a Albaba, Hamzeh |e verfasserin |4 aut | |
| 700 | 1 | |a Moura, Shari |e verfasserin |4 aut | |
| 700 | 1 | |a Grant, Robert C |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Jessica K |e verfasserin |4 aut | |
| 700 | 1 | |a Mbabaali, Faridah |e verfasserin |4 aut | |
| 700 | 1 | |a Pasternack, Danielle |e verfasserin |4 aut | |
| 700 | 1 | |a Lungu, Ilinca M |e verfasserin |4 aut | |
| 700 | 1 | |a Bartlett, John M S |e verfasserin |4 aut | |
| 700 | 1 | |a Ghai, Sangeet |e verfasserin |4 aut | |
| 700 | 1 | |a Lemire, Mathieu |e verfasserin |4 aut | |
| 700 | 1 | |a Holter, Spring |e verfasserin |4 aut | |
| 700 | 1 | |a Connor, Ashton A |e verfasserin |4 aut | |
| 700 | 1 | |a Moffitt, Richard A |e verfasserin |4 aut | |
| 700 | 1 | |a Yeh, Jen Jen |e verfasserin |4 aut | |
| 700 | 1 | |a Timms, Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Krzyzanowski, Paul M |e verfasserin |4 aut | |
| 700 | 1 | |a Dhani, Neesha |e verfasserin |4 aut | |
| 700 | 1 | |a Hedley, David |e verfasserin |4 aut | |
| 700 | 1 | |a Notta, Faiyaz |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Julie M |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Malcolm J |e verfasserin |4 aut | |
| 700 | 1 | |a Gallinger, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Knox, Jennifer J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research : an official journal of the American Association for Cancer Research |d 1995 |g 24(2018), 6 vom: 15. März, Seite 1344-1354 |w (DE-627)NLM09444479X |x 1557-3265 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2018 |g number:6 |g day:15 |g month:03 |g pages:1344-1354 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/1078-0432.CCR-17-2994 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2018 |e 6 |b 15 |c 03 |h 1344-1354 | ||